STAT+: FTC loses its bid to block Novant’s hospital merger in North Carolina
A federal judge ordered Wednesday that Novant Health can move forward with its plan to…
Category: STAT+
STAT+: Appeals court overturns Sutter Health’s victory in $400 million antitrust case
When Sutter Health was on trial for anticompetitive conduct in 2022, the San Francisco jury…
STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of…
STAT+: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Student group that ranked med schools over industry conflicts votes to accept pharma funding
An organization devoted to educating future doctors about conflicts of interest will now accept industry…
STAT+: Gilead to pay $40 million to settle claims it delayed newer HIV treatment to boost profits
Gilead Sciences agreed in principle to pay $40 million to more than 2,600 AIDS patients…
STAT+: As Washington mulls new AI rules, startup leaders want a seat at the table
WASHINGTON — In San Francisco, Y Combinator’s firebrand chief executive Garry Tan is one of…
ASCO Takeaways: Winners, snoozers, the China question and the art of cancer care
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: U.S. drug shortages have reached a decade high and are lasting longer, too
Amid rising concern over prescription drug shortages, a new report finds that the number of…
STAT+: Medicare Advantage plan’s quality ratings were incorrectly calculated by government, judge rules
The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan,…
STAT+: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly…
STAT+: Tracking the FDA advisory panel on MDMA therapy for PTSD
Good morning, and welcome to STAT’s live blog of the Food and Drug Administration’s scientific…
STAT+: How a device maker inundated pain patients with unwanted batteries and surprise bills
Michelle Bean is drowning in batteries she doesn’t need. For two years, the batteries and…
STAT+: Illumina board agrees to spin off Grail, as divestment plans proceed
Illumina said Monday afternoon that its board of directors had approved a spin-off of its…
.jpg)
STAT+: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility
A leading contract research organization has agreed to pay $35 million — including the largest-ever…
STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with…
STAT+: Becton Dickinson to buy Edwards patient monitoring unit for $4.2 billion
Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells…
STAT+: A short-lived Medicaid freakout sends insurers’ stocks diving
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Delfi Diagnostics announces key data, study design for its liquid biopsy test
CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen…
STAT+: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies
Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two…
STAT+: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows
Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions…
STAT+: Elevance PBM’s president out as customers complain of prescription chaos
Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company…
STAT+: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial
Intellia Therapeutics said Saturday that the first 10 patients to receive a CRISPR-based treatment for…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
STAT+: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market
LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew…
STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
STAT+: HHS: Change Healthcare can make data breach notifications in lieu of hospitals
Change Healthcare can notify patients whose sensitive health information has been exposed as a result…
STAT+: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on…
STAT+: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company…
STAT+: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial
Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease…
STAT+: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows
Most physicians who endorsed a prescription drug or medical device on X — formerly known…
STAT+: Did Sarepta Therapeutics earn $4 billion from exon-skipping drugs that don’t work?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Value-based payment is getting renewed attention. What it means isn’t getting any clearer
WASHINGTON — Nearly 20 years ago, policymakers had an epiphany: The health care system should…
STAT+: Clinical lab trade group sues FDA over plan to regulate lab-developed tests
A group representing clinical labs across the country sued the Food and Drug Administration on…
STAT+: Akili, maker of a video game to treat ADHD, acquired for $34 million
A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video…
STAT+: Scientists install ‘window’ in the skull to record brain activity using ultrasound
Researchers may have a new way to watch the human brain pulse, thanks to an…
STAT+: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Biohaven protein-degrader drug falls short of investor expectations in early-study test
Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a…
STAT+: Reports: Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio
LONDON — Merck is buying ophthalmology-focused startup EyeBio in a deal worth up to $3…
STAT+: Health insurers boast to investors about using AI, but they’d rather not talk about it
Health insurers are telling shareholders that they are ramping up the use of artificial intelligence…